J I Clark

Summary

Affiliation: Loyola University Medical Center
Country: USA

Publications

  1. ncbi request reprint Case report and brief review: IL-2-induced myocarditis
    Robert M Eisner
    Department of Internal Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Cancer Invest 22:401-4. 2004
  2. doi request reprint Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer
    Joseph I Clark
    Edward Hines, JR VA Hospital, Hines, IL 60411, USA
    Med Oncol 30:358. 2013
  3. pmc Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, Division of Hematology Oncology, 2160 South First Avenue, Maywood, IL 60153, USA
    Cancer 116:424-31. 2010
  4. doi request reprint Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer
    Joseph I Clark
    Department of Medicine, Division of Hematology Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
    Am J Clin Oncol 32:396-400. 2009
  5. ncbi request reprint Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer
    J I Clark
    Edward Hines, JR VA Hospital, Hines, IL, USA
    Lung Cancer 34:271-7. 2001
  6. ncbi request reprint Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
    J Immunother 30:839-46. 2007
  7. ncbi request reprint Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma
    J I Clark
    Department of Medicine, Division of Hematology Oncology, Loyola University Medical Center Cardinal Bernardin Cancer Center, 2160 South First Avenue, Maywood, IL 60153, USA
    Cancer 92:2334-40. 2001
  8. ncbi request reprint Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Clin Oncol 21:3133-40. 2003
  9. ncbi request reprint A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population
    J I Clark
    Edward Hines Jr VA Hospital, IL, USA
    Ann Oncol 13:606-13. 2002
  10. ncbi request reprint Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma
    J I Clark
    Edward Hines, Jr, Veterans Affairs Hospital, Hines, Illinois 60141, USA
    Clin Cancer Res 5:2374-80. 1999

Detail Information

Publications36

  1. ncbi request reprint Case report and brief review: IL-2-induced myocarditis
    Robert M Eisner
    Department of Internal Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Cancer Invest 22:401-4. 2004
    ..It may be reasonable to make the diagnosis on clinical grounds, while providing supportive care. Future investigation is required to better understand the pathophysiology and what factors may influence expression of this toxicity...
  2. doi request reprint Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer
    Joseph I Clark
    Edward Hines, JR VA Hospital, Hines, IL 60411, USA
    Med Oncol 30:358. 2013
    ....
  3. pmc Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, Division of Hematology Oncology, 2160 South First Avenue, Maywood, IL 60153, USA
    Cancer 116:424-31. 2010
    ..We conducted a multicenter phase 2 trial to better define the clinical efficacy of thalidomide and temozolomide and the immune modulatory effects of thalidomide, when combined with temozolomide, in patients with metastatic melanoma...
  4. doi request reprint Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer
    Joseph I Clark
    Department of Medicine, Division of Hematology Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
    Am J Clin Oncol 32:396-400. 2009
    ..This phase I study was designed to determine the maximum tolerated dose (MTD) and preliminary efficacy of docetaxel with concurrent radiotherapy (RT), in high-risk squamous cell carcinoma of the head and neck...
  5. ncbi request reprint Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer
    J I Clark
    Edward Hines, JR VA Hospital, Hines, IL, USA
    Lung Cancer 34:271-7. 2001
    ....
  6. ncbi request reprint Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
    J Immunother 30:839-46. 2007
    ..Despite clinical efficacy, the study was closed prematurely owing to excess toxicity. Although all serious adverse events resolved, this degree of toxicity is unacceptable for an outpatient treatment regimen...
  7. ncbi request reprint Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma
    J I Clark
    Department of Medicine, Division of Hematology Oncology, Loyola University Medical Center Cardinal Bernardin Cancer Center, 2160 South First Avenue, Maywood, IL 60153, USA
    Cancer 92:2334-40. 2001
    ..The authors investigated the use of paclitaxel and carboplatin in a limited Phase II study in recurrent or metastatic SCCHN to evaluate tumor response, time to progression, survival, and toxicities of this regimen...
  8. ncbi request reprint Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Clin Oncol 21:3133-40. 2003
    ..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)...
  9. ncbi request reprint A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population
    J I Clark
    Edward Hines Jr VA Hospital, IL, USA
    Ann Oncol 13:606-13. 2002
    ..The identical regimen has shown promise in advanced melanoma...
  10. ncbi request reprint Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma
    J I Clark
    Edward Hines, Jr, Veterans Affairs Hospital, Hines, Illinois 60141, USA
    Clin Cancer Res 5:2374-80. 1999
    ..Despite the reasonable tolerability of this daily low-dose s.c. regimen, we conclude that this regimen is an ineffective treatment in metastatic renal cell carcinoma patients who are incapable of tolerating high-dose i.v. IL-2...
  11. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  12. ncbi request reprint New therapeutic strategies for the treatment and prevention of head and neck cancer
    M W Lingen
    Department of Pathology, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    Expert Opin Investig Drugs 9:2855-72. 2000
    ..Finally, we will discuss the rationale for the use of anti-angiogenic agents as one possible means of developing new chemopreventive protocols that result in reduced toxicity while maintaining similar clinical efficacies...
  13. ncbi request reprint Neoadjuvant therapy: an emerging concept in oncology
    Tawee Tanvetyanon
    Division of Hematology Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA
    South Med J 98:338-44. 2005
    ..To date, the survival benefits of neoadjuvant therapy for resectable non-small cell lung, esophageal, gastric, and prostate cancer remains under investigation...
  14. ncbi request reprint Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026
    Laura F Hutchins
    Division of Hematology Oncology, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Cancer 110:2269-75. 2007
    ..Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma. Endpoints were 6-month progression-free survival rate, response rate, and toxicity...
  15. ncbi request reprint Posterior marginal mandibulectomy in the management of cancer of the oral cavity and oropharynx
    Guy J Petruzzelli
    Department of Otolaryngology Head and Neck Surgery, Division of Plastic and Reconstructive Surgery, Loyola University Medical Center, Maywood, IL 60153, USA
    Otolaryngol Head Neck Surg 129:713-9. 2003
    ..To review the history and surgical technique with emphasis on functional as well as oncologic outcomes...
  16. doi request reprint Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 113:2139-45. 2008
    ..The authors tested the efficacy of a regimen including TMZ, thalidomide, and whole brain radiation therapy (WBRT) in patients with brain (CNS) metastases from melanoma...
  17. ncbi request reprint Metastatic renal cell carcinoma
    Robert C Flanigan
    Department of Urology, Loyola University Medical Center, Cardinal Bernardin Cancer Center and Hines VA Hospital, Maywood, IL 60153, USA
    Curr Treat Options Oncol 4:385-90. 2003
    ....
  18. ncbi request reprint Nephrectomy in metastatic renal cell carcinoma
    Steven C Campbell
    Department of Urology, The Cardinal Bernardin Cancer Center, Loyola University Medical Center, Hines VA Hospital, 2160 South 1st Avenue, Building 54, Room 237, Maywood, IL 60153, USA
    Curr Treat Options Oncol 4:363-72. 2003
    ....
  19. ncbi request reprint Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients
    E Y Nikitina
    Cardinal Bemardin Cancer Center, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Cancer Res 7:127-35. 2001
    ..These data demonstrate that DCs transduced with the wild-type p53 gene were able to induce a specific antitumor immune response. This offers a new promising approach to immunotherapy of cancer...
  20. ncbi request reprint Passive seeding in metanephric adenoma: a review of pseudometastatic lesions in perinephric lymph nodes
    Gladell P Paner
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Arch Pathol Lab Med 129:1317-21. 2005
    ..We conclude that this phenomenon is understudied and underrecognized and can easily be mistaken for metastasis...
  21. ncbi request reprint Metanephric adenosarcoma in a young adult: morphologic, immunophenotypic, ultrastructural, and fluorescence in situ hybridization analyses: a case report and review of the literature
    M M Picken
    Department of Pathology, Loyola University Medical Center, Chicago, Illinois 60153, USA
    Am J Surg Pathol 25:1451-7. 2001
    ..We conclude that the spectrum of metanephric neoplasia should be expanded to include malignant stromal variants, and we propose the term "metanephric adenosarcoma" for the present case...
  22. ncbi request reprint Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019
    Kathy S Albain
    Loyola University Stritch School of Medicine, Maywood, IL, USA
    J Clin Oncol 20:3454-60. 2002
    ....
  23. pmc Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA University of Chicago Cancer Research Center, Chicago, IL, USA
    Lancet Oncol 10:247-57. 2009
    ..In this multi-institutional phase I/II study we combined an EGFR inhibitor, erlotinib, with an anti-VEGF antibody, bevacizumab...
  24. doi request reprint A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma
    Frederick Locke
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 65:509-14. 2010
    ..GM-CSF has a theoretical advantage of immune potentiation. These considerations supported the study of oxaliplatin, docetaxel, and GM-CSF in patients with advanced melanoma...
  25. ncbi request reprint Phase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patients
    D M Lathers
    Research Service, Hines Veterans Affairs Hospital, Hines, Illinois 60141, USA
    Hum Immunol 62:1282-93. 2001
    ..Although no clinical responses were observed, results of these pilot studies showed that 25-hydroxyvitamin D(3) reduced the presence of immune suppressive CD34(+) cells and improved immune competence of HNSCC patients...
  26. ncbi request reprint Metastatic juxtaglomerular cell tumor in a 52-year-old man
    Xiuzhen Duan
    Department of Pathology, Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
    Am J Surg Pathol 28:1098-102. 2004
    ..In consideration of the characteristic morphologic features, immunohistochemistry, and the presence of rhomboid crystals of proto-renin, the diagnosis was modified to malignant juxtaglomerular cell tumor...
  27. ncbi request reprint Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults
    Paul N Meyer
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Am J Clin Pathol 128:70-9. 2007
    ..Various treatments met with minimal success. Unlike pediatric patients, the adult patients followed a rapidly terminal course, with a mean survival of 18 months after diagnosis (range, 10-24 months)...
  28. pmc A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer
    Richard T Lee
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 6:21-4. 2008
    ..SB-715992 is a new agent that inhibits the function of a mitotic kinesin known as kinesin spindle protein and leads to cell death...
  29. ncbi request reprint Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report
    Janet C Ruzich
    Hematology and Oncology, Cardinal Bernadin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, Illinois, USA
    Head Neck 24:406-10. 2002
    ..Patients with metastatic disease have been treated with chemotherapy, but, again, response rates have been low and of short duration...
  30. ncbi request reprint Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis
    Mohtashim Naeem
    Loyola University Medical Center, Maywood, IL, USA
    Hum Pathol 33:1182-7. 2002
    ..Furthermore, determination of c-kit in SCLC may have a prognostic value in SCLC patients...
  31. pmc Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center Vanderbilt, University Medical Center, Section of Hematology Oncology, 777 Preston Research Bldg, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:2292-8. 2008
    ..We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial...
  32. ncbi request reprint Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
    Kim Margolin
    City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Clin Cancer Res 13:3312-9. 2007
    ..This phase I study was designed to determine the maximum tolerated dose (MTD) and safety of BAY 50-4798, screen for tumor response, and assess pharmacokinetics...
  33. ncbi request reprint Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3
    Deanne M R Lathers
    Research Service 151, Ralph H Johnson Veterans Affairs Medical Center, 109 Bee Street, SC 29401 5799, Charleston, USA
    Cancer Immunol Immunother 53:422-30. 2004
    ..In contrast, 25-hydroxyvitamin D(3) treatment did not modulate plasma IL-1beta, IL-2, IL-4, IL-6, IL-10, GM-CSF, or TGF-beta levels...
  34. ncbi request reprint A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007
    Francis P Worden
    Department of Internal Medicine, Division of Medical Oncology, University of Michigan, Ann Arbor, Michigan 48109 0848, USA
    Cancer 107:319-27. 2006
    ..To validate these results and to determine the feasibility of this combination, a Phase II study was conducted by the Southwest Oncology Group (SWOG S0007)...
  35. ncbi request reprint Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 10:5022-6. 2004
    ....
  36. ncbi request reprint Renal tumor with overlapping distal nephron morphology and karyotype
    Valerie Lindgren
    Department of Pathology, University of Illinois at Chicago, Chicago, Ill, USA
    Arch Pathol Lab Med 128:1274-8. 2004
    ....